Investor Relations

Major Marketed Products

This data is provided as a convenience and for informational purposes only for our shareholders and investors. It is not intended to provide medical advice to consumers or health care professionals. This data was current as of July 2008. Lilly assumes no duty to update this data for changes since that date.

Lilly Newsroom to search press releases for Lilly Products

Date	Product
2005	Byetta® for type 2 diabetes for use in combination with a thiazolidinedione (2007) (in collaboration with Amylin Pharmaceuticals, Inc.)
2004	Cymbalta® for major depressive disorder for diabetic peripheral neuropathic pain (2004) for generalized anxiety disorder (2007) for the maintenance treatment of major depressive disorder (2007) for the management of fibromyalgia (2008) (in collaboration with Quintiles Transnational Corp. in the U.S., Shionogi & Co. Ltd. in Japan, and with Boehringer Ingelheim elsewhere in the world)
2004	Alimta® for malignant pleural mesothelioma for second-line treatment of non-small-cell lung cancer (2004) for first-line treatment of non-small-cell lung cancer (2008)
2004	Symbyax® for bipolar depression
2004	Yentreve® for stress urinary incontinence (approved and launched outside the U.S.)
2003	Cialis® for erectile dysfunction for once-daily use (2007)
2003	Strattera® for attention-deficit hyperactivity disorder in children, adolescents, and adults for maintenance treatment of attention-deficit/hyperactivity disorder in children and adolescents.
2002	Forteo® for treatment of men and postmenopausal women with osteoporosis who are at high risk for a fracture for the treatment of glucocorticoid-induced osteoporosis (2008; Europe)
2001	Xigris® for severe sepsis in adult patients at high risk of death
1999	Actos® for type 2 diabetes (in collaboration with Takeda outside the U.S.)
1998	Evista® for prevention of osteoporosis in postmenopausal women for treatment of osteoporosis in postmenopausal women (1999) for reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis (2007) for reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer (2007)
1996	Zyprexa® for schizophrenia for acute bipolar mania (2000) Zyprexa® Zydis® tablet (2000) for schizophrenia maintenance (2001) as combination therapy with lithium or valproate for acute bipolar mania (2002) for bipolar maintenance (2003) Rapid-acting IntraMuscular formulation (2004) Zyprexa® granules (2004; launched in Japan only)
1996	Humalog® Lyspro Rapid Acting Insulin for treatment of type 1 and type 2 diabetes Humalog® Mix 75/25 (1999) Humalog® Mix 50/50 (1999)
1995	Gemzar® for non-small-cell lung cancer for pancreatic cancer (1996) for bladder cancer (1999; approved and launched outside the U.S.) for metastatic breast cancer (2003) for recurrent ovarian cancer (2004) for biliary tract cancer (2006; Japan)
1995	ReoPro® for prevention of cardiac ischemic complications in patients undergoing coronary intervention, such as angioplasty for unstable angina associated with stent procedure (1997) (in collaboration with Centocor, except in Japan)
1987	Humatrope® for growth failure caused by pediatric growth hormone deficiency for replacement therapy for adult growth hormone deficiency (1995) for short stature caused by Turner syndrome (1997) for idiopathic short stature (2003)
1983	Humulin® for type 1 and type 2 diabetes